Create Free Account

By creating account you will get access to hot stocks & personalised emails

Radiopharm Theranostics Ltd

Healthcare AU RAD

0.021AUD
-0.002(8.70%)

Last update at 2024-12-19T05:11:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.020.10
LowHigh

Fundamentals

  • Previous Close 0.02
  • Market Cap56.50M
  • Volume4981298
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-32.20199M
  • Revenue TTM1.96M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM -13.32167M
  • Diluted EPS TTM-0.12

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30
Income before tax -34.57319M -30.29458M -0.48519M
Minority interest - - -
Net income -34.61119M -30.33898M -0.48519M
Selling general administrative 15.26M 12.44M 0.48M
Selling and marketing expenses - - -
Gross profit 0.29M 0.00883M -
Reconciled depreciation 3.30M 2.98M -
Ebit -28.59060M -23.92633M -1.16341M
Ebitda -31.19057M -20.94484M -
Depreciation and amortization - 2.98M -
Non operating income net other - - -
Operating income -34.48710M -23.92633M -0.48475M
Other operating expenses - 20.95M 0.00883M
Interest expense 0.26M 9.35M 0.00000M
Tax provision 0.04M 0.04M 0.00000M
Interest income 0.09M 9.35M -
Net interest income 0.06M -9.34974M -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense 0.04M 0.04M -
Total revenue 0.29M 0.00883M 0.00000M
Total operating expenses - 20.95M -
Cost of revenue - - -
Total other income expense net -0.12405M -1.02849M -
Discontinued operations - - -
Net income from continuing ops -34.61119M -30.33898M -
Net income applicable to common shares -34.61119M -30.42001M -1.16446M
Preferred stock and other adjustments - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 72.04M 74.95M 83.38M 0.03M
Intangible assets - 58.54M 56.08M -
Earning assets - - - -
Other current assets 3.29M 0.13M 0.23M -
Total liab 44.68M 30.57M 20.42M 0.16M
Total stockholder equity 28.12M 44.38M 62.96M -0.12470M
Deferred long term liab - - - -
Other current liab 11.14M 8.16M 6.69M -
Common stock 100.68M 97.23M 86.76M 0.00100M
Capital stock - 97.23M 86.76M -
Retained earnings -111.33877M -65.35386M -30.82417M -0.48519M
Other liab - 16.14M 12.54M -
Good will - - - -
Other assets - 0.04M 0.04M 0.00000M
Cash 18.58M 11.70M 26.98M 0.03M
Cash and equivalents - - - -
Total current liabilities 17.58M 13.23M 7.88M 0.16M
Current deferred revenue - - - -
Net debt -18.57504M - -26.97911M -
Short term debt - 0.00000M 0.00000M 0.06M
Short long term debt - - - -
Short long term debt total - - - -
Other stockholder equity 37.93M 12.51M 7.11M 0.36M
Property plant equipment - 0.07M 0.00158M -
Total current assets 22.85M 16.30M 27.26M 0.03M
Long term investments - - - -
Net tangible assets - -14.15675M 6.89M -0.12470M
Short term investments - - - -
Net receivables 0.99M 4.47M 0.06M 0.00635M
Long term debt - - - -
Inventory - - - -
Accounts payable 6.43M 2.96M 1.19M 0.06M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income 0.85M - 7.03M -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 49.09M 0.04M 0.04M -
Deferred long term asset charges - - - -
Non current assets total 49.19M 58.65M 56.12M -
Capital lease obligations - - - -
Long term debt total - 0.00000M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30
Investments -1.53068M -0.04000M -0.04000M
Change to liabilities 2.35M 2.53M 0.24M
Total cashflows from investing activities -1.53068M -28.37865M -28.37865M
Net borrowings - -0.05900M 0.14M
Total cash from financing activities 9.22M 65.11M 0.14M
Change to operating activities 0.10M -0.22882M -0.22882M
Net income -34.61119M -30.42001M -1.16446M
Change in cash -15.28004M 26.95M 0.07M
Begin period cash flow 26.98M 0.03M -
End period cash flow 11.70M 26.98M 0.03M
Total cash from operating activities -23.20180M -9.90682M -0.07898M
Issuance of capital stock 10.07M 70.00M -
Depreciation 3.30M 2.98M 2.98M
Other cashflows from investing activities 0.00000M 0.00883M 0.00883M
Dividends paid - - -
Change to inventory - - -
Change to account receivables 1.51M -0.05013M -0.01523M
Sale purchase of stock 10.07M -4.83089M 0.00100M
Other cashflows from financing activities -0.85476M 0.01000M -4.83089M
Change to netincome 4.16M 15.28M 0.86M
Capital expenditures 0.05M 28.34M 0.00275M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 1.70M 0.00883M -
Stock based compensation - - -
Other non cash items - - -
Free cash flow -24.73248M -28.33865M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RAD
Radiopharm Theranostics Ltd		 -0.002 8.70% 0.02 - - 32.18 2.16 141.26 0.42
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. The company was incorporated in 2021 and is based in Carlton, Australia.

Radiopharm Theranostics Ltd

62 Lygon Street, Carlton, VIC, Australia, 3053

Key Executives

Name Title Year Born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Founder & Exec. Chairman 1956
Mr. Riccardo Canevari MD, CEO & Director NA
Mr. Phillip Hains CFO & Company Sec. NA
Prof. David Mozley Chief Medical Officer & Scientific Advisory Board Chair NA
Mr. Vittorio Puppo M.D. Chief Operating Officer NA
Dr. Thomas H. Tulip Ph.D. Chief Technical Officer 1953
Dr. Scot L. Harper Ph.D. Sr. VP of Clinical Operations 1957
Mr. Bill Regan Sr. VP of Regulatory Strategy NA
Mr. Nathan Jong C.A. Company Sec. NA
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Founder & Executive Chairman 1956

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.